Abstract Background Glioma is the most common type of malignant brain tumor, presenting substantial treatment challenges. LRRC15, a leucine-rich repeat (LRR) protein and a type I transmembrane protein, has been linked to cancer progression but its specific role in glioma has not been fully elucidated.Methods This research examined LRRC15 expression in various cancers with a focus on glioma, utilizing data from The Cancer Genome Atlas (TCGA). We explored the correlation between LRRC15 expression and survival (both overall and disease-specific) in glioma patients, and investigated the relationship of LRRC15 with immune cell infiltration in the tumor microenvironment. Functional impacts of LRRC15 on glioma cell proliferation, motility, and invasiveness were assessed through colony formation assays, transwell migration tests, and wound healing assays.Results LRRC15 expression was notably elevated in glioma among other cancers. Higher levels of LRRC15 correlated with adverse survival outcomes in glioma patients. Functionally, reducing LRRC15 expression in glioma cell lines diminished their proliferative, motile, and invasive properties.Conclusions Our findings highlight LRRC15 as a significant prognostic biomarker and potential therapeutic target in glioma. Inhibiting LRRC15 could decelerate tumor progression and enhance clinical outcomes, representing a promising advancement in glioma therapy.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: